Ruconest
Ruconest, with the active ingredient conestat alfa, is a recombinant human C1 esterase inhibitor used to treat acute attacks of hereditary angioedema (HAE) in patients with C1-INH deficiency. It is produced by Pharming Group N.V. in the milk of transgenic rabbits and formulated as an intravenous preparation.
HAE arises from insufficient functional C1 esterase inhibitor, leading to unregulated activation of the complement and
Ruconest is approved for the treatment of acute HAE attacks in eligible patients in various regulatory jurisdictions.
Administration is intravenous. A single dose is given at 50 units per kilogram body weight, up to
Symptom relief commonly begins within 30 to 60 minutes after administration, with improvement continuing for several
Common adverse effects include nausea, headache, fever, and infusion-related reactions. Severe hypersensitivity is rare; thromboembolic events